Biologics in Severe Asthma: Optimizing Therapeutic Selection and Patient Outcomes

Target Audience
This activity was developed for pulmonologists, allergists, immunologists, primary care physicians, and other healthcare professionals involved in the care of patients with severe asthma.

Program Overview
This case-based activity focuses on considerations, including phenotypes and biomarkers, in individualizing treatment with the 5 monoclonal antibodies currently approved for severe asthma in the United States. The role of shared decision-making is discussed as an approach to individualizing therapy and improving patient outcomes. Clinical criteria for assessing treatment response to biologic therapy and how to modify therapy when needed are also discussed.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Discuss the latest evidence regarding the pathophysiology of severe asthma
Explain the clinical implication of the latest scientific developments in the area of biologic therapies for the management of severe asthma
Differentiate biologic therapies currently available for the management of patients with severe asthma
Implement biologic therapy for a patient with severe asthma taking into account the latest available data and genetic factors